GeneDx Holdings (WGS) financial statements
GeneDx Holdings reported revenue of $428M in fiscal 2025, up 13.9% a year over 6 years.
Net income was -$21M and the operating margin -3.1%, against -15.5% in 2019.
Free cash flow was $14M.
The diluted share count rose 23098073% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from GeneDx Holdings's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $196M | $179M | $212M | $235M | $203M | $305M | $428M |
| Cost of revenue | $113M | $175M | $229M | $261M | $113M | $111M | $129M |
| Gross profit | $83M | $4M | -$17M | -$27M | $90M | $194M | $298M |
| Research and development | $35M | $73M | $105M | $86M | $58M | $46M | $72M |
| Selling, general and admin | $69M | $164M | $319M | $338M | $200M | $172M | $239M |
| Operating income | -$30M | -$242M | -$446M | -$668M | -$181M | -$23M | -$13M |
| Interest expense | $783,000 | $2M | $3M | $3M | — | — | — |
| Pre-tax income | -$30M | -$241M | -$245M | -$598M | -$177M | -$53M | -$21M |
| Income tax | $0 | $0 | $0 | -$49M | -$926,000 | -$343,000 | -$116,000 |
| Net income | -$30M | -$241M | -$245M | -$549M | -$176M | -$52M | -$21M |
| EPS (diluted) | -$264,056.00 | -$47,036.00 | -$2.27 | -$53.63 | -$7.23 | -$1.94 | -$0.73 |
| Diluted shares | 0M | 0M | 108M | 10M | 24M | 27M | 29M |
| Gross margin | 42.2% | 2.2% | -7.8% | -11.4% | 44.4% | 63.6% | 69.7% |
| Operating margin | -15.5% | -134.9% | -210.3% | -284.5% | -89.2% | -7.6% | -3.1% |
| Net margin | -15.1% | -134.6% | -115.6% | -233.9% | -86.8% | -17.1% | -4.9% |
Balance sheet
Fiscal years, from GeneDx Holdings's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $115M | $108M | $401M | $124M | $130M | $141M | $171M |
| Receivables | — | $32M | $27M | $43M | — | $38M | $74M |
| Inventory | — | $25M | $33M | $14M | $9M | $11M | $14M |
| Total current assets | — | $174M | $484M | $213M | $182M | $198M | $268M |
| Property, plant and equipment | — | $63M | $63M | $52M | $32M | $33M | $46M |
| Goodwill | — | $0 | $0 | — | — | $0 | $14M |
| Total assets | — | $252M | $554M | $491M | $419M | $419M | $524M |
| Total current liabilities | — | $73M | $101M | $144M | $59M | $55M | $109M |
| Long-term debt | — | $19M | $11M | $6M | $53M | $52M | $48M |
| Total liabilities | — | $247M | $166M | $237M | $191M | $174M | $216M |
| Shareholders' equity | -$89M | -$330M | $388M | $254M | $228M | $245M | $308M |
| Net debt | -$115M | -$87M | -$390M | -$113M | -$46M | -$32M | -$52M |
Cash flow
Fiscal years, from GeneDx Holdings's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19M | -$93M | -$190M | -$319M | -$180M | -$28M | $33M |
| Capital spending | $15M | $32M | $21M | $14M | $6M | $5M | $19M |
| Free cash flow | -$34M | -$125M | -$211M | -$333M | -$186M | -$34M | $14M |
| Stock-based compensation | $5M | $120M | $219M | $42M | -$326,000 | $9M | $32M |
| Net borrowing | $0 | $16M | $0 | $0 | $49M | $0 | $0 |
| Free cash flow margin | -17.4% | -69.8% | -99.5% | -142.1% | -91.8% | -11.1% | 3.3% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for WGS.
Open WGS in InvestinglyQuestions
What was GeneDx Holdings's revenue in 2025?
$428M in fiscal 2025, from its 10-K filing.
How much free cash flow does GeneDx Holdings generate?
$14M in fiscal 2025 (operating cash flow minus capital spending).
From GeneDx Holdings's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.